

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number  
WO 03/029269 A1

(51) International Patent Classification: C07J 71/00

(21) International Application Number: PCT/EP02/10946

(22) International Filing Date:  
30 September 2002 (30.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01123458.0 28 September 2001 (28.09.2001) EP

(71) Applicant (for all designated States except US): GLY-COMED SCIENCES LIMITED [AU/AU]; P.O. Box 115, Turramurra NSW 2074 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LAWSON, Chris [GB/GB], Dextra Laboratories, Ltd., Earley Gate, Whiteknights Road, Reading RG6 6BZ (GB).

(74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, 81675 Munich (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/029269 A1

(54) Title: SOLVENT EXTRACTION PROCESS

(57) Abstract: The present invention relates to an improved extraction process for an alkaloid glycoside extract from the species *Solanum*.

WO 03/029269

PCT/EP02/10946

1

## Solvent Extraction Process

The present invention relates to an improved extraction process for an alkaloid glycoside extract from the species *Solanum*.

A standard mixture of solasonine glycosides, isolated from the fruits of *Solanum sodomaem*, is known as BEC. BEC is a crude mixture of glycoalkaloids comprising the triglycerides solasonine (approx. 33%), solamargine (33%) and an undefined fraction which has been referred to as "di and monoglycosides".

The process for making BEC involves homogenizing the fruits of *Solanum sodomaem* in a large volume of acetic acid, filtering off the liquor through muslin, precipitating the glycosides with ammonia and repeating the steps several times (WO 00/6 11 53; Planta Medica 1987, 1: 59-62). The yield of the solasonine glycoside mixture is very low (approx. 0.8%).

BEC is incorporated in very small amounts into a topical cream (Curaderm®) which is used to treat skin lesions such as sunspots and keratosis.

BEC has also been reported to exhibit preferential cytotoxicity for various human cancer cells (WO 91/10743).

While BEC is of sufficient quality to be used in small quantities in over the counter (OTC) topical cream formulations, it does not meet the regulatory requirements for pharmaceutical use. Thus, the individual process steps of the standard process for the preparation of BEC are not defined to GMP (Good Manufacturing Process) in terms of scale up, definition of yield, composition and product quality.

Moreover, other than the presence of the triglycosides solasonine and solamargine the BEC mixture has never been analyzed regarding the precise nature of the active ingredients, the assumption being that all glycoside components are active in combination.

The present invention is directed towards a novel solanum glycoside extract comprising the active glycoside components in high purity meeting the requirements of GMP.

WO 03/029269

PCT/EP02/10946

2

The present invention thus provides a novel extraction process for the preparation of a solanum glycoside extract consisting essentially only of the active solanum glycosides.

Also provided is a novel very sensitive HPLC method for the analysis of solanum glycoside extracts. This novel HPLC method employs an ACE 5 C18 (V99-140) column (length 25cm + 1cm guard cartridge; particle size 5 $\mu$ m; internal diameter 4.6mm; pore size 100Å), Advanced Chromatography Technologies (ACT) (obtainable from HiChrom, Theale).

The mobile phase used at a flow rate of 0.7ml/min was 75% 20mM (pH 2.95) phosphate buffer, 25% acetonitrile using a Spectra-Physics SP 8800 Ternary HPLC Pump. Detection was carried out at 205nm with a Spectra-Physics, Spectra 1000 Variable Wavelength Detector.

Based on extensive analysis of the BEC mixture it was shown that in addition to the triglycosides solasonine and solamargine a diglycoside component is present in an amount of approximately 30%. It was surprisingly found that the diglyceride component does not appear to exhibit any activity in cytotoxicity in various experimental cancer cell lines.

In accordance with the present invention a solasodine glycoside extract is provided consisting essentially of the triglycendes solasonine and solamargine.

Preferably the extract is of close to 100% purity with no measurable or only trace amounts of the inactive diglycoside component.

Preferably, solasonine is present in the final extract in an amount between 30-50% whereas solamargine is present in an amount of 40-60%.

The extract of the present invention may be obtained by the following process:

The solanum plant tissue is dried and comminuted to a powder. The powder is subjected to an alcohol extraction. Following the removal of the alcohol the dried extract is dissolved in acid and centrifuged. The supernatant is precipitated under alkaline conditions. The acid/alkaline precipitation steps may be repeated several times.

WO 03/029269

PCT/EP02/10946

3

The precipitate is then thoroughly washed with water and dried and further purified by silica gel chromatography.

As a *Solanum* glycoside source any of the plants of the *Solanum* species may be used. Preferably, however, the extract of the invention is obtained from *Solanum sodomaem*. It has been found that the highest yields of the two components of the extract solamargine and solasonine may be obtained from the lyophilized fruit of *Solanum sodomaem*.

While the extraction process may be carried out using any pharmaceutically acceptable volatile alcohol including methanol, ethanol, propanol and isopropanol, the extraction is most preferably carried out using methanol.

For the precipitation step the dried extract may be treated with any volatile and weak acid and alkaline reagent. It has been found that optimal results may be obtained using acetic acid and concentrated ammonia.

For the chromatographic purification using silica gel chromatography, the freeze dried extract may be dissolved in methanol. Before elution the silica gel is washed with acetone. The elution is preferably carried out using a gradient of methanol and acetone.

In the subsequent example the extraction process of the invention is exemplified in detail below.

## Example 1

### 1.1 Preparation of fruit

The fruits of *Solanum Sodomaem* were cut in half and dried by lyophilization. The dried fruits were then comminuted to a powder. The final dried, ground powder from a yield of 5 kg of fruits was 898 g.

WO 03/029269

PCT/EP02/10946

4

## 1.2 Solvent extraction of glycoalkaloids

The powdered fruit (approx. 230g each) was divided between 3 Soxhlet thimbles (Whatman cellulose, 60 x 180mm), and four extractions conducted for each with 1 litre methanol (Labscan, HPLC grade). The first extraction (1 litre methanol) was conducted for 7.5 hours before the methanol was removed by evaporation and the resulting extracts analysed by HPLC. The 3 subsequent extractions were with 750ml methanol to find the point at which all glycoalkaloids were completely extracted. The four extractions were labelled A, A<sub>1</sub>, A<sub>2</sub> and A<sub>3</sub>, respectively. The concentrations of glycoalkaloid in the the four separate extractions are shown in Table 1.

Table 1. Concentration of glycoalkaloids in the Extract

	Solasonine, mg/ml by HPLC	Solamargine, mg/ml by HPLC
A	7.9	9.4
A <sub>1</sub>	2.2	2.6
A <sub>2</sub>	0.16	0.16
A <sub>3</sub>	0.06	0.07

### 1.3.1. Production scale purification of Extract A

The dry and partially evaporated extracts A, A<sub>1</sub> and A<sub>2</sub> (A<sub>3</sub> abandoned due to lack of useful product) were pooled and evaporated to yield a pooled dry extract (62.23g). The extracts were dissolved in acetic acid (2 litres, 3%(v/v)) and the slightly turbid solution clarified by centrifugation (6,000rpm, 20mins). The supernatant was collected and a

WO 03/029269

PCT/EP02/10946

5

small amount of green precipitate discarded. The sample was then filtered to remove a few small remaining lumps of green precipitate.

#### 1.3.1.1 *1<sup>st</sup> Precipitation with ammonia*

The filtrate was adjusted to pH 9 by addition of concentrated ammonia and the precipitate allowed to settle for 1 hour before centrifugation (6,000rpm, 20mins). This gave a gel-like precipitate, which was easily re-dissolved in approx. 1 litre 3%(v/v) acetic acid, such that the final volume of sample was 1.25 litres.

#### 1.3.1.2 *2<sup>nd</sup> Precipitation with ammonia*

The pH of the sample was adjusted to 9 by addition of concentrated ammonia and the precipitate was allowed to settle for a few minutes before centrifugation (6,000rpm, 20mins).

#### 1.3.1.3 *Washing of precipitate*

The precipitate was re-dispersed and thoroughly mixed with de-ionised water (6 x 250ml), and collected by centrifugation. This procedure was repeated once and the pellets were drained.

#### 1.3.1.4 *Freeze-drying of product A*

The pellets were dissolved in ammonium acetate, pH 4.5 (3%(v/v) acetic acid adjusted to pH 4.5 with concentrated ammonia to give a solution of ammonium acetate at pH 4.5). The final volume of solution at this stage was 360ml. The sample was polish filtered through a glass fibre filter (Whatman GF/B) prior to weighing into plastic containers (16cm x 16cm x 6cm). The sample was then frozen and subsequently freeze-dried.

The yield (by weight) of the extract was approx. 1.14% of the original weight of the whole fruit, or 6.45 % of the dried powdered fruit.

WO 03/029269

PCT/EP02/10946

6

The composition of the freeze dried extract was determined by HPLC. It was found to contain approx. 33% solasonine, 40.1% solamargine but no detectable traces of the diglycoside component.

#### 1.4 The freeze dried extract A

##### Chromatographic purification of Extract A

A column was packed with dry Silica Gel (406.6g, column dimensions: 7.5cm x 18cm). Freeze-dried Extract A (13.59g) was weighed out and dissolved in methanol (250ml). Silica gel (106g) was added, and the slurry was dried to a fine powder by evaporation. The slurry was then applied to the top of the silica column and a layer of silver sand was added (1cm approx.). The column was washed with acetone (1 litre) before elution of the glycoalkaloids. The column was eluted at a flow rate of 1 litre/hr with a 4-step gradient of methanol:acetone as follows:

Step 1: methanol (30%(v/v)):acetone (70%(v/v)), 2 litres

Step 2: methanol (40%(v/v)):acetone (60%(v/v)), 2 litres

Step 3: methanol (60%(v/v)):acetone (40%(v/v)), 1 litre

Step 4: methanol (100%(v/v)) 1.5 litres

##### 1.4.1 Pooling of fractions

Fractions (51 x 25ml) were collected when step 1 of the gradient was applied, in order to monitor where the solamargine and solasonine started to elute. After this, larger 500ml fractions were collected throughout until after step 4. The progress of the purification was monitored by TLC. Fractions containing the desired endproducts (solamargine, solamargine plus solasonine, as well as the solasonine) were pooled. The fractions were dried by rotary evaporation and processed immediately as described below.



WO 03/029269

PCT/EP02/10946

7

#### 1.4.2 Ammonia precipitation

The dried pooled fractions were dissolved in acetic acid (900ml, 3%(v/v)) and adjusted to pH 9 by addition of concentrated ammonia. The resulting precipitate was collected by centrifugation (6,000rpm/20 mins).

#### 1.4.3 Washing of precipitates and freeze-drying

The resulting precipitate was washed three times with water, collected by centrifugation, and frozen at  $-20^{\circ}\text{C}$ , prior to re-dissolution in acetic acid (1.6 litres, 0.1%(v/v)). The sample was then divided equally into 8 containers and freeze-dried.

#### 1.4.4 Yields and purities of final purified products

The freeze-dried products were weighed and stored desiccated under vacuum at  $+4^{\circ}\text{C}$ . The samples were then analysed for purity (against a BEC standard) by HPLC. The results are presented in Table 2.

**Table 2 Yields and Purities of Final product**

Sample	Yield G	*% recovery	HPLC Analysis		
			% Solasonine	% Solamargine	% Total by HPLC
A	8.49	88.0	40.5	55.3	97.5

#### 1.5 **Chemical and microbiological analysis of original BEC plant extract and final product prepared in accordance with the invention**

Samples of the prior art BEC product as well as a product in accordance with the present invention were analysed for moisture content and for microbial, pesticide and heavy metal content.

WO 03/029269

PCT/EP02/10946

8

**1.5.1 Microbial analysis**

A sample of the prior art BEC product, together with the final purified product of the invention were sent for microbial analysis, moisture, methanol, ash and heavy metal analysis.

Results for these analyses are summarised in Table 3.

**Table 3 Summary of analytical results for BEC plant material and Purified product A**

Test	BEC product	A
Bacterial count	>1500per 50mg	<1 per 10mg
Fungal Count	>1500 per 50mg	<1 per 10mg
Residue on ignition, %	6.7	0.4
Water, % m/m	1.99	5.66
Methanol, $\mu\text{g/g}$	350	<50
Heavy metals, ppm as Pb	10	<10
<u>Heavy Metals:</u>		
Cd, mg/kg	<0.02	
Pb, mg/kg	<0.10	
Hg, mg/kg	0.01	
As, mg/kg	0.03	

WO 03/029269

PCT/EP02/10946

9

## 2. Conclusions

Solvent extraction using methanol has proven to be very successful in the extraction of the selective triglycosides solasonine and solamargine with little or no contamination with the diglycoside.

In order to obtain the final high purity product the extract was subjected to a silica gel chromatography. Preferably, in order to optimize the recovery of solasonine, which has a low solubility in acetone, a graded eluent comprising methanol and acetone should be applied.

It was shown that the process of the present invention effectively removes the third component which is present in BEC in amounts in excess of 30%.

Following evaporation of the solvent from the sample, a single re-precipitation with ammonia and washing gives rise to a clean product, which can easily be freeze-dried from solution in aqueous ammonium acetate. The volatile constituents are removed during the freeze-drying process. It is preferable that the final purification step is carried out within a 24 hour period in order to optimise the appearance of the final product.

### 2.1 Product Purity

The process developed here gives a significantly improved product compared with that obtained by the Cham process (2), in terms of its appearance, purity, moisture, and heavy metal content. The final freeze-dried product was a granular off-white powder. The purity of the product was in the range 92.7 – 99.3% (HPLC analysis), compared with a typical purity of 65 – 70% obtained by the previous method. Moisture content was also lower (4.0 – 5.7% compared with 7% obtained previously), and heavy metal contamination was extremely low.

WO 03/029269

PCT/EP02/10946

10

## CLAIMS

1. A process for the preparation of a glycoside extract comprising the following steps:
  - a) ground, dried plant tissue of the species *Solanum* is subjected to alcohol extraction using a pharmaceutically acceptable volatile alcohol;
  - b) the extract obtained is dried and dissolved in a weak volatile acid and centrifuged;
  - c) the supernatant is precipitated using a volatile base;
  - d) the precipitate is thoroughly washed and dried.
2. A process according to claim 1, wherein the steps b) and c) are repeated several times.
3. The process according to claim 1 or 2, wherein the volatile alcohol is methanol.
4. The process according to anyone of claims 1 to 3, wherein the volatile acid is acetic acid.
5. The process according to anyone of claims 1 to 4, wherein the base is concentrated ammonia.
6. The process of anyone of claims 1 to 5, wherein the dried plant tissue is lyophilized fruit of *Solanum sodomaeum*.
7. A process for the isolation of an extract of the triglycosides solasonine and solamargine in substantially pure form comprising subjecting the extract as obtained according to anyone of claims 1 to 6 to silica gel chromatography.
8. The process according to claim 8, wherein the eluent used is a methanol/acetone gradient.
9. A solasonine triglycoside extract comprising the triglycosides solasonine and solamargine having a purity of above 90%.

WO 03/029269

PCT/EP02/10946

11

10. The solasodine triglycoside extract of claim 9, wherein the ratio of solasonine:solamargine is in the range of 0.3-0.7:0.4-0.8.
11. The solasodine triglycosides extract of claim 9 or 10, wherein the ratio of solasonine:solamargine is in the range of 0.4-0.6:0.5-0.7.
12. The solasodine triglycoside extract of claim 9, wherein the ratio of solasonine:solamargine is 0.7:0.5.
13. The solasodine triglycoside extract of anyone of claims 9 to 12 obtainable according to anyone of claim 8 or 9.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/10946

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07J71/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 61153 A (CURA NOMINEES PTY LTD ; CHAM BILL E (AU)) 19 October 2000 (2000-10-19) cited in the application	1-13
X	the whole document, in particular: page 4, lines 12-17; page 11, lines 11-16; page 14, line 25 - page 15, line 30; claims 16, 17	9-11, 13
Y	WO 91 10743 A (CURA NOMINEES PTY LTD) 25 July 1991 (1991-07-25) cited in the application	1-13
X	the whole document, in particular: page 11, lines 19-27	9-11, 13
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

9 January 2003

Date of mailing of the international search report

20/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Fitz, W

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/10946

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ROCCA M.A.: "STEROIDALCOMPONENTS OF SOLANUM VIARUM, DUN" REV. FAC. FARM. ODONTOL. ARARAQUARA, vol. 10, no. 2, 1976, pages 329-342, XP008011336	1-13
X	the whole document, in particular: page 330;	9,13
Y	US 3 960 839 A (GUERRERO MILTON) 1 June 1976 (1976-06-01)	1-13
X	the whole document, in particular: column 1, lines 47-54; column 4, lines 14,15	9,13
Y	FEWELL, A.M. ET AL.: "INTERACTIONS BETWEEN THE GLYCOALKALOIDS SOLASONINE AND SOLAMARGINE IN RELATION TO INHIBITION OF FUNGAL GROWTH" PHYTOCHEMISTRY, vol. 37, no. 4, 1994, pages 1007-1011, XP008011328	1-13
X	the whole document, in particular: page 1009, Table 1, entries 5 and 10; page 1010, column 1, last paragraph	9-11,13
Y	CHAND R.: "ISOLATION AND PURIFICATION OF SOLASODINE FROM SOLANUM KHASIANUM" INDIAN DRUGS, vol. 30, no. 12, 1993, page 650 XP008011333	1-13
	the whole document, in particular: first column, third paragraph	
Y	BANERJEE, S.K. ET AL.: "CHEMICAL INVESTIGATION OF THE BERRIES OF SOLANUM AETHIOPIUM" PLANTA MEDICA, vol. 25, 1974, page 216-218 XP008011331	1-13
	the whole document, in particular: page 216, last 2 lines; page 217, line 6	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/10946

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0061153	A	19-10-2000	WO 0061153 A1	19-10-2000
			AU 3545400 A	14-11-2000
			EP 1181022 A1	27-02-2002
WO 9110743	A	25-07-1991	AT 188036 T	15-01-2000
			AU 654474 B2	10-11-1994
			AU 7159491 A	05-08-1991
			WO 9110743 A1	25-07-1991
			BR 9105952 A	17-11-1992
			CA 2073855 A1	19-07-1991
			DE 69131861 D1	27-01-2000
			DE 69131861 T2	18-05-2000
			EP 0515386 A1	02-12-1992
			JP 3168542 B2	21-05-2001
			KR 213805 B1	02-08-1999
			SG 50585 A1	20-07-1998
			US 5958770 A	28-09-1999
US 3960839	A	01-06-1976	BR 7404139 A	03-02-1976
			CA 1029010 A1	04-04-1978
			CH 608245 A5	29-12-1978
			DD 113753 A5	20-06-1975
			FR 2277820 A1	06-02-1976
			JP 50135209 A	27-10-1975
			NL 7404924 A	14-10-1975
			AU 6538574 A	14-08-1975
			BE 814177 A1	25-10-1974
			GB 1465392 A	23-02-1977